Volume 16, number 1

Epidemiology and Risk Factor of Lung Cancer in Morocco

Amal Haimer*1, Souad Belamalem1, Faouzi Habib2, Abdelrhani Mokhtari , Abdelmajid Soulaymani1and Hinde Hami1

1Laboratory of Genetics and Biometry, Faculty of Science, Ibn Tofail University, Kenitra, Morocco.

2Al-Azhar Oncology Center, Rabat, Morocco.

Corresponding Author E-mail: amal.haimer@gmail.com

ABSTRACT: The aim of this study is to describe the epidemiological characteristics of lung cancer in Morocco. This is a descriptive retrospective analysis of lung cancer cases, diagnosed and treated at Al Azhar Oncology Center in Rabat over a period of 11 years, between 2005 and 2015. Among the 615 cases that were diagnosed with lung cancer at Al Azhar Oncology Center, 85.85% were male and 14.15% female, the mean age of men with lung cancer was 59.8 ± 11.2 years while that of women was 58.6 ± 12 years. During the study period, there were 129 deaths from this type of cancer, of which 89.9% were men and 10.08% were women. The maximum frequency of death was observed in patients aged between 40 and 60 years with 54.80%. Of all diagnosed cases, 2.40% were diagnosed with metastatic disease. The majority of patients received chemotherapy treatment with 47%, followed by patients who received radiotherapy with 42.3%. On the other hand, the study shows that there is an association between the risk of progression to death and smoking. Lung cancer is dreaded especially in the male population with a high number of cases and lethality as well as a poor prognosis.

KEYWORDS: Epidemiological Profile; Lung Cancer; Retrospective Study

Copy the following to cite this article:

Haimer A, Belamalem S, Habib F, Mokhtari A, Soulaymani A, Hami H. Epidemiology and Risk Factor of Lung Cancer in Morocco. Biosci Biotech Res Asia 2019;16(1).

Copy the following to cite this URL:

Haimer A, Belamalem S, Habib F, Mokhtari A, Soulaymani A, Hami H. Epidemiology and Risk Factor of Lung Cancer in Morocco. Biosci Biotech Res Asia 2019;16(1). Available from: https://bit.ly/2WzO1uF

[ HTML Full Text]

Back to TOC